Who Will Be the Next Moderna? SLS, BEAM, NTLA and the Biotech Stocks That Could See the Next Major Re-Rating

Why Everyone Is Looking for the “Next Moderna”

On August 19, 2026, the market received the kind of news that can change the valuation of an entire technology platform. Moderna and Merck announced that the Phase 3 INTerpath-001 study, conducted in 1,137 patients with completely resected high-risk melanoma, met both key endpoints: recurrence-free survival and distant metastasis-free survival for intismeran autogene in combination with Keytruda compared to Keytruda alone. The companies also reported that no new safety signals had emerged. At the time of the first announcement, however, hazard ratios, survival curves, subgroup analyses and full details had not yet been published.^[1]

The stock market reaction was extreme. Moderna closed Aug. 18 at $62.96 and Aug. 19 at $174.38, a close-to-close increase of approximately 176.9%. It is a movement that cannot be explained solely by the potential value of a single product in a single indication. The market suddenly placed greater credibility on the idea that the personalized mRNA platform could produce repeatable, expandable, and commercially relevant cancer therapies.

The result didn’t come out of nowhere. In June, five-year data from Phase 2b KEYNOTE-942/mRNA-4157-P201 showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death for the intismeran-Keytruda combination compared to Keytruda alone. The exploratory analysis of overall survival showed a favorable trend, but with a still wide confidence interval. Intismeran is designed to encode up to 34 neoantigens selected based on the mutational signature of the individual patient’s tumor.^[2]

This distinction is the core of this analysis. Many biotechs have promising technology. Some have proof-of-concept in a few patients. Very few get to the point where a controlled, registrational or near-registrational trial demonstrates that the technology is not just elegant: it is capable of producing a reproducible clinical benefit that can support regulatory decisions and commercial scale.

Moderna also remains a company with a very different financial structure from the smaller biotechs that might follow its path. As of June 30, 2026, it had approximately $6.9 billion in cash, equivalents and investments, while continuing to record losses and face individual program failures or slowdowns, such as failure to meet early success criteria in the interim Phase 3 of the norovirus vaccine.^[3] The message is important: a platform does not eliminate clinical risk. However, it offers multiple attempts, reusable infrastructure and the possibility that one success makes up for multiple failures.

What It Really Means to Become the “Next Moderna”

The expression can mean at least four different things. Confusing them leads to superficial rankings.

The next Moderna won’t necessarily be another mRNA company. It will be the company whose first breakthrough results force the market to reevaluate multiple programs at once — or, in the case of SLS, to recognize that a pre-commercial biotech can become a potentially registration-stage oncology company.

A true platform has reusable elements: design tools, intellectual property, delivery processes, CMC capabilities, manufacturing, biomarkers and regulatory know-how. The value comes not only from the number of programs listed on a slide, but from the possibility of reducing time, cost and marginal risk when moving from the first to the second and third assets.

A validation moment can exist even in a less platform-like company. If GPS demonstrated a statistically and clinically convincing benefit in overall survival, SELLAS would not suddenly become a miniature Moderna. However, the credibility of the asset, the path toward a BLA filing, the relevance of the WT1 target, the negotiating leverage and the way in which the market evaluates SLS009 would change. This is enough to include SLS in the search for the next major biotech re-rating.

How the Ranking Was Built

The ranking is not a list of stocks to buy and does not attempt to predict which stock will offer the highest return. It evaluates eight companies across six dimensions, keeping confirmed facts separate from editorial interpretations.

1. Platform breadth and reusability. How many programs can be generated by the same engine? Are delivery, manufacturing and design tools proprietary or third-party dependent?
2. Quality of human validation. Is there patient data? Are they biomarkers, responses, functional endpoints or survival? Is the study controlled or single-arm?
3. Regulatory proximity. Is the program Phase 1, pivotal, BLA/NDA, approved or marketed? Can the endpoint support a regulatory application?
4. Financial strength. Cash, net loss, cash burn, runway, debt, convertibles, warrants and ATMs determine how much time the company can give to science without resorting to new equity.
5. Clinical and commercial scalability. A personalized therapy, an autologous cell therapy, an in vivo infusion and an oral drug have radically different costs, production capacities and access barriers.
6. Room for re-rating. How much of the success is already reflected in the price? A company may have excellent data but even higher expectations.

Eight Companies, Eight Ways to Answer the Same Question

The question “Who will be the next Moderna?” appears singular, but it actually contains several different questions. Which company has the largest platform? Which is closer to a regulatory decision? Which has the most explosive catalyst? Which can finance development without heavily diluting shareholders? And which still has a valuation that leaves room for a re-rating?

There is no overall winner. Beam Therapeutics offers the most balanced combination of platform, clinical data, pivotal development and capital. Intellia is closer to turning in vivo CRISPR editing into a registered product. SELLAS presents the closest and most binary pivotal catalyst, but has a less integrated platform and arrives at the readout after a strong rise. Arcturus is the most literal successor to mRNA, while CRISPR Therapeutics is already beyond the question: its platform has produced an approved drug. Sana and Prime Medicine concentrate an important part of the scientific asymmetry, but also of the risk of clinical translation and financing. BioNTech already belongs to the same strategic category as Moderna.

The overall score is not a performance prediction

The “Next Moderna fit” score rewards the balance between technology, data, capital and proximity to the catalyst. It does not automatically reward the company with the greatest theoretical upside. A small-cap ahead of a Phase 3 can move more than a well-financed company; however, it can also lose much of its value if the trial fails. Likewise, a platform company with multiple programs may offer a less binary distribution of outcomes, but take years for the market to fully recognize the technology.

Prices, Performance and Sentiment: The Market Is Not Starting From Zero

Good technology is not automatically a good market setup. The price incorporates expectations, implied probabilities, liquidity, short positioning, retail participation and the company’s ability to raise capital. The same news can produce a huge re-rating in a depressed stock and a modest reaction in a stock that has already anticipated the result.

This point is particularly important for SELLAS. Between the week beginning August 25, 2025 and the week beginning August 17, 2026, SLS went from a weekly close of approximately $1.92 to approximately $13.86, an approximate increase of more than 620%. In the same interval Moderna recorded a similar performance after the shock of August 19th. Beam gained about 78%; Arcturus, despite the strong summer rebound, remained negative on the comparative horizon. The data is approximate price returns on weekly bars and does not include dividends or total return adjustments.^[25]

Why normalize prices

A comparison between absolute prices would be meaningless: a share at 3 dollars is no cheaper than one at 100 dollars. By indexing prices to 100 we observe the trajectories. SLS began pre-empting REGAL several months before the readout; MRNA experienced a discontinuity concentrated in one session; BEAM, NTLA and CRSP showed more progressive movements and linked to a sequence of milestones.

Retail Sentiment: Useful as a Thermometer, Dangerous as Evidence

As of the August 20, 2026 review, the Stocktwits normalized sentiment score was extremely bullish for MRNA and very high for ARCT, CRSP and BNTX. SLS showed a score of 60, labeled bullish, with approximately 86.9% of messages classified as bullish in the available sample. The data come from a self-selected retail community, change rapidly and do not represent a scientific survey or clinical probability.^[24]

Three common mistakes when looking for the next big biotech winner

1. Confusing price and capitalization. Share count matters. SLS is an instructive example: the price has gone up, but the number of shares has also gone up.
2. Using the delay of an event as a surrogate for effectiveness. In event-driven blinded trials, the speed of pooled events does not reveal which arm is performing better.
3. Look only at the upside and not the value already incorporated. The higher the expectation, the more a positive but not exceptional result can become a sell-the-news.

Cash, Burn Rate, Runway and Dilution: Time Is a Clinical Variable

Science takes time, and time must be funded. In pre-commercial biotech, the cash position determines whether the company can complete a trial, prepare a regulatory application, build production capacity and negotiate a partnership from a position of strength. It also determines how much of the future value will remain with existing shareholders.

As of June 30, 2026, CRISPR Therapeutics had approximately $2.36 billion in cash, equivalents and marketable securities; Beam of approximately 1.15 billion; Intellia of approximately 628 million. Arcturus, Sana, SELLAS and Prime Medicine were between approximately 109 and 192 million. BioNTech, with approximately 16.6 billion euros in cash and securities investments, belongs to a different financial category and is not included in the graph in dollars to avoid an artificial comparison between currencies and scales.^{[4][11][13][15][16][18][19]}

R&D spending: intensity does not automatically mean productivity

Beam incurred approximately $95.1 million in R&D expenses in Q2 2026, Intellia $82.6 million, and CRISPR Therapeutics $67.2 million. Prime Medicine, Sana, Arcturus and SELLAS operate on smaller scales. The difference reflects number and phase of programs, staffing, manufacturing, global trials and non-cash components; it does not in itself allow us to establish which company makes best use of capital.

Net loss is another imperfect indicator. Includes non-cash components, appreciation, equity compensation and partnership revenue, and does not coincide with cash burn. SELLAS had a much smaller quarterly loss than the large gene-editing platforms; However, a smaller structure does not automatically mean lower financial risk, because access to capital and needs following a Phase 3 can change rapidly.

A useful ratio, as long as it is not called a runway

Dividing cash by last quarter’s net loss yields an intuitive number of theoretical quarters, but it’s just a mechanical exercise. Excludes milestones, revenue, license payments, capex, working capital, debt, new offerings, warrants and spend acceleration. It is useful for comparing the order of magnitude and intensity of consumption, not for predicting the date of the next harvest.

Stated runways

Beam indicated a runway through mid-2029, including expected capital from Sixth Street. Arcturus indicated coverage until the end of 2028; Intellia at least in 2028; SANA until mid-2027; Prime Medicine “into 2027”. SELLAS declared that the cash was sufficient for at least the twelve months following the publication of the Q2 results, therefore at least until August 2027 based on that formulation. These indications depend on programs, spending and access to external sources and may change.

Dilution: The risk that often comes before the drug

Dilution risk is not uniform. CRISPR Therapeutics and BioNTech can fund many programs with large reserves, although CRSP has also increased cash through convertibles. Beam has a strong position but incurs a high expense. Intellia has capital to accompany the BLA and commercial preparation, but the transition to commercial-stage requires investment. Sana and Prime Medicine have shorter runways. SELLAS has strengthened the balance sheet through warrant exercises, but has simultaneously expanded the share count and maintains an authorized ATM.

SELLAS Life Sciences: Not the Closest Platform to Moderna, but Perhaps the Most Moderna-Like Catalyst

SELLAS occupies a special position. It is not the company that most resembles Moderna from an industrial point of view: it does not have a single proprietary engine from which all the programs were born. Galinpepimut-S, or GPS, is a WT1-directed immunotherapy licensed from Memorial Sloan Kettering Cancer Center; SLS009, or tambiciclib, is a selective CDK9 inhibitor acquired under license from GenFleet. The two assets have different mechanisms, origins and development paths.^[10]

SELLAS, however, is one of the companies closest to an event capable of transforming its status. If REGAL demonstrated that GPS statistically and clinically convincingly improves overall survival in AML, the discussion would quickly move from “small-cap with an experimental peptide vaccine” to “possible oncology company with a registrational asset, a validated target and a second program in development”. This is the correct parallel with Moderna: not technological identity, but the transformative power of pivotal validation.

REGAL: what Phase 3 really measures

REGAL is a randomized, open-label, international Phase 3 study comparing GPS with the best available therapy as maintenance in patients with acute myeloid leukemia who have achieved a second or subsequent complete remission. The primary endpoint is overall survival. The event-driven design provides for the final analysis after 80 deaths. The study enrolled 127 patients.^[7]

The choice of overall survival makes the trial particularly important. OS is a clinically direct endpoint, less dependent on radiological interpretations or surrogates. However, it is exposed to variables following randomization: transplants, salvage therapies, biological heterogeneity and prognostic differences can influence the curves. To evaluate the result it will not be enough to read “endpoint reached”. Hazard ratio, confidence interval, median OS, shape and separation of curves, proportionality of risk, maturity of follow-up and sensitivity analysis will be needed.

In January 2025, after the interim activated at the sixtieth event, the Independent Data Monitoring Committee recommended continuing the trial without modifications. The company reported that the futility test had passed and that no safety issues had emerged. In August 2025, a further periodic review again recommended continuation without modification.^[6]

The count of events: because 78 does not mean knowing the result

SELLAS communicated 72 pooled events as of 26 December 2025 and 78 events as of 11 May 2026. In the Q2 update on August 11, 2026, the company continued to describe REGAL as approaching its 80th event, without formally announcing that the threshold had been reached. As of the date of this report, 20 August 2026, there was no press release declaring the eightieth event in the official sources examined.^[4][5]

It is understandable that investors interpret a slower maturation of events as a possible signal of better survival. But the reasoning has a fundamental limit: the events are pooled. If patients in both arms lived longer than expected, the 80th event would arrive more slowly without implying a relative advantage of GPS. Changes in care, transplants, patient selection and enrollment patterns may also influence the timing.

Reaching the eightieth event also does not coincide with the immediate publication of the topline data. This is followed by confirmation and reconciliation of events, database locks, quality checks, blinded review, execution of the statistical plan, unblinding and preparation of the press release. The duration depends on the quality of the database and the operating protocol. The market must distinguish between event trigger and data release.

Which outcome would be truly transformative?

A strong scenario would require more than a p-value below the threshold. The benefit should be clinically relevant and sufficiently robust to compare with the variability of the AML population in second or subsequent remission. A favorable hazard ratio accompanied by consistent curve separation and credible results in sensitivity analyses would strengthen the regulatory case. A formally positive result but with modest benefit, wide intervals or dependence on a few patients could produce a much more complex reaction.

The population is rare and at high risk, an element that can increase the importance of a real benefit but also complicate the launch. Even after a positive Phase 3, SELLAS should discuss the regulatory package with the FDA, complete the CMC documentation, define the manufacturing process and prepare pharmacovigilance and marketing. A positive result does not equal automatic approval.

GPS and WT1: biological breadth does not mean universal validation

GPS uses peptides derived from WT1 to stimulate an immune response against tumor cells that express the target. WT1 is reported in numerous hematologic and solid malignancies, and SELLAS describes a potential opportunity in over twenty tumor types. The biological breadth is interesting, but must be interpreted with rigor: the expression of a target in many indications does not demonstrate that the same vaccine, in the same formulation and in the same setting, will produce clinical benefit in all.

A positive REGAL would validate GPS in the setting studied and increase the credibility of WT1 as a therapeutic target. It could make it rational to reopen combinations, previous lines or other neoplasms, and attribute greater optionality to GPS+. However, it would not automatically demonstrate efficacy in solid tumors or in every WT1-positive disease. The distinction avoids the classic platform mistake: transforming a theoretical opportunity into a clinically de-risked pipeline.

SLS009: the second asset that changes the distribution of risk

The presence of SLS009 prevents the SELLAS story from being a pure all-or-nothing on GPS. Tambiciclib is a highly selective inhibitor of CDK9, a transcription regulator involved in the dependence on anti-apoptotic proteins such as MCL1. In the Phase 2 program in relapsed or refractory AML, SELLAS reported an objective response rate of 33% in the entire evaluable population, 40% at the recommended dose of 30 mg twice weekly, 44% in patients with myelodysplasia-related features and 50% in ASXL1-mutated or M4/M5 morphology subgroups. The company reported median overall survival in the range of 8.8–8.9 months in some groups, compared to lower historical benchmarks.^[8]

The signals warranted a new frontline randomized trial in approximately 80 patients with newly diagnosed AML. The program focuses on patients who are molecularly less likely to fully benefit from azacitidine and venetoclax and those who show early resistance. SELLAS had enrolled 28 patients at the time of the Q2 update and indicated a topline date of Q4 2026.^[4][9]

The frontline study is important for three reasons. It introduces a randomized comparison, therefore a more interpretable test of the single-arm Phase 2. Test a biomarker-driven selection, central to increasing the probability that the benefit is concentrated in the most biologically sensitive patients. Finally, it creates a second potentially definitive catalyst a few months after REGAL.

Balance sheet: stronger, but not without cost to shareholders

SELLAS closed Q2 2026 with approximately $138.3 million in cash and cash equivalents, R&D expenses of approximately $6.3 million, G&A of approximately $4.4 million and a net loss of approximately $9.6 million. The balance sheet is much more robust than in previous phases and allows the company to address REGAL, SLS009 and regulatory activities without a stated immediate need for capital.^[4]

The strengthening, however, came largely through warrant exercises and equity instruments. The share count outstanding was approximately 153.1 million as of December 31, 2025, 181.3 million as of March 31, 186.0 million as of May 11 and 201.9 million as of June 30, 2026: an increase of approximately 31.9% in six months. The company had also established an ATM program of up to $150 million; as of March 31, there were no sales made through that program.^[10]

Valuation: the surprise no longer starts from an ignored micro-cap

Using the approximately 201.9 million shares outstanding as of June 30 and the closing of $13.85 on August 19, a indicative capitalization of approximately 2.8 billion. The calculation is not fully diluted, does not subtract cash, does not include subsequent years and does not replace an updated enterprise value. It serves to show that the market has already attributed a much higher value to SELLAS than a year earlier.

This reevaluation does not invalidate the thesis, but it changes the asymmetry. When SLS was worth a few hundred million, a positive Phase 3 could produce a re-rating from a much lower base. At an indicative capitalization close to 2.8 billion, the market already assigns a significant probability and value to success. An excellent result can still justify a new leap; a marginal result may not meet expectations; a failure can produce a severe compression towards the value of SLS009, cash and residual optionality.

Beam Therapeutics: The Most Complete Combination of Platform, Data and Capital

Beam Therapeutics is the candidate that most resembles Moderna in the phases prior to full validation: not because it develops RNA, but because it is building a repeatable technological infrastructure. Base editing aims to modify individual DNA bases without necessarily producing double-strand breaks, with the aim of making more precise corrections and potentially reducing some unwanted consequences of traditional editing. The company integrates editor design, delivery, manufacturing and clinical development into ex vivo and in vivo programs.

The bottom line is that Beam is no longer just in preclinical slide territory. BEAM-302, developed for alpha-1 antitrypsin deficiency, produced clinical data that allowed the company to open a global pivotal cohort. At the 60 mg dose, Beam reported a mean steady-state level of total AAT of 16.1 µM; all patients above the protective threshold of 11 µM; Corrected AAT equal to approximately 94% of total AAT; and 84% average reduction in mutant Z-AAT protein. Follow-up was up to twelve months, with a safety profile described as favorable at the time of the update.^[12]

Why BEAM-302 is platform validation, not just a single asset

BEAM-302 uses lipid delivery to the liver and modifies the PiZ variant of the SERPINA1 gene in vivo. If the program demonstrated clinical efficacy, durability and safety on larger numbers, it would validate multiple components simultaneously: the base editor, the guide, the delivery, the dose control, the production process and the ability to obtain a therapeutic correction directly in the body.

This is the difference between a drug and a platform. The success of a single program does not guarantee that all future assets will work, because target, fabric and delivery can change. But it reduces uncertainty about part of the infrastructure. In particular, a robust result in the liver could increase the credibility of future programs using similar delivery in the same organ.

Risto-cel: a second path to value

Beam also has risto-cel, an ex vivo therapy for sickle cell disease. The company indicated the possibility of submitting a BLA by the end of 2026. This creates a different structure from a single-asset biotech: BEAM-302 represents the in vivo ambition, while risto-cel may offer a closer regulatory and commercial path. The ex vivo program must however deal with the competitive reality of CASGEVY and other sickle cell therapies, with conditioning, center capacity, patient selection and reimbursement.

The combination is important because it diversifies the type of trial. An ex vivo therapy can validate cellular editing and manufacturing, but does not demonstrate systemic delivery in vivo. BEAM-302 can validate in vivo delivery, but does not replace evidence of ultimate clinical benefit. Together, the programs build a more credible platform than a single readout would.

Balance Sheet and Runway

As of June 30, 2026, Beam had approximately $1.15 billion in cash, equivalents and marketable securities. The company indicated a runway through mid-2029, including expected capital from a deal with Sixth Street. In Q2, R&D spending was around 95.1 million and the net loss was around 122.7 million.^[11]

This financial position is a concrete advantage. It allows the company to support pivotal development, BLA preparation, manufacturing and pipeline without being forced to raise capital after each milestone. It does not eliminate dilution risk: a company with expensive plans can raise capital even with a long runway, especially after a rally. However, it reduces the risk that the science will be interrupted due to lack of funds.

The limits of the Beam thesis

The BEAM-302 data are very interesting, but a biomarker correction does not automatically coincide with clinical benefit on lung or liver disease. Durability, inter-patient variability, dose-response relationship, immune response, liver toxicity and evaluation of off-targets will be important. Even a theoretically more precise technology must demonstrate an adequate safety margin when the change is permanent.

Base editing also presents concentrated platform risk: an unexpected problem in editors, delivery or production could affect multiple programs. The breadth of the pipeline is an advantage when the infrastructure works; it can become a negative multiplier if a common risk emerges.

Intellia Therapeutics: The Company Closest to Commercializing In Vivo CRISPR

Intellia represents perhaps the most direct parallel with the moment Moderna has just experienced. The market no longer has to wonder whether in vivo CRISPR can produce a biological signal in a few patients. Lonvoguran ziclumeran, or lonvo-z, has completed a positive Phase 3 in hereditary angioedema and the company has initiated a rolling BLA. If approved, the product could become one of the first large-scale commercial demonstrations of gene editing administered directly into the body.

In Phase 3 HAELO, a single dose of lonvo-z reduced the average monthly attack rate to 0.26 compared to 2.10 with placebo, a relative reduction of approximately 87%. 62% of treated patients were free of attacks and without long-term prophylaxis compared to 11% in the placebo group. The trial produced an easily understandable clinical separation: not just a biomarker, but a reduction in disease-defining events.^[14]

Why value goes beyond hereditary angioedema

Lonvo-z uses lipid nanoparticles to deliver the CRISPR editor to the liver and inactivate KLKB1, reducing kallikrein production. An approval would validate the ability to administer a therapy once, permanently modify a gene in the body and achieve a lasting clinical effect. It would not automatically demonstrate the effectiveness of each Intellia program, but it would reduce uncertainty about liver delivery, the production process, monitoring and the relationship with regulators.

This is the “Moderna-like” part: a product can become a proof of the platform. The value of the follow-on assets does not have to be added as if they were already approved, but the probability attributed by the market can increase when the common elements have passed a Phase 3.

The regulatory and commercial path

Intellia had started the rolling submission of the BLA and indicated acceptance of the application in the second half of 2026, with a possible US launch in the first half of 2027.^[13] However, the transition from clinical-stage to commercial-stage requires more than one approval. The company must build center access, physician education, pharmacovigilance, long-term follow-up capacity and a reimbursement model for a one-time treatment.

The economic comparison will not only be with the annual cost of existing prophylaxis. Payer and doctors will evaluate durability, irreversibility, safety, need for monitoring and availability of effective alternatives. Lifelong therapy can offer enormous value, but makes any long-term uncertainty more sensitive.

The second axis: ATTR

Intellia also develops nexiguran ziclumeran, or nex-z, in transthyretin amyloidosis. The program aims to permanently reduce TTR production through liver editing. The potential market is larger than HAE, but the competition is also intense: stabilizers, RNA silencers and other therapies have data, approvals and commercial infrastructure. The value of nex-z will depend on the ability to demonstrate not only a reduction in protein, but a competitive clinical benefit and a safety profile that justifies a permanent modification.

Balance Sheet and Runway

As of June 30, 2026, Intellia had approximately $628.4 million in cash, cash equivalents and marketable securities, with runway indicated at least in 2028. In Q2 R&D spending was around 82.6 million and the net loss around 106.6 million.^[13] It is a sufficient position to accompany the BLA and commercial preparation, but the construction of a launch organization and the continuation of multiple Phase 3s may increase the need.

The risk that does not disappear with a positive Phase 3

Lonvo-z permanently modifies the genome. Regulators and clinicians will evaluate off-target, immunogenicity, hepatic events, dose variability and prolonged follow-up. A favorable initial profile is necessary but does not conclude the evaluation. The rarity of HAE allows for a focused launch, but limits the absolute number of patients and requires identification and conversion from effective chronic therapies.

There is also the risk of concentration in hepatic delivery. The liver is now the most accessible tissue for many in vivo platforms. Demonstrating the ability to reach other organs would be a further and more difficult step. Intellia can become a large liver editing company without necessarily solving the entire systemic delivery problem.

CRISPR Therapeutics: Not the Next Moderna, Because Its Platform Has Already Passed the Test

CRISPR Therapeutics is in a different category. CASGEVY, developed with Vertex, is an approved therapy for sickle cell disease and transfusion-dependent beta-thalassemia in multiple jurisdictions. The company has therefore already achieved what younger candidates are looking for: demonstrating that an editing technology can cross clinical, regulatory and commercial development.

As of Q2 2026 the company reported approximately $76 million in CASGEVY revenues and approximately 90 patients cumulatively infused. The data is still initial compared to the potential of the eligible population, but it shows that the product has entered the real world.^[15]

Regulatory validation does not eliminate the access problem

CASGEVY requires collection of the patient’s stem cells, ex vivo editing, myeloablative conditioning and reinfusion in specialized centers. It is a sophisticated therapy, potentially transformative, but not easy to scale. The bottleneck isn’t just producing the drug: it’s identifying patients, qualifying them, setting up the center, managing conditioning, coordinating logistics and reimbursement, and supporting long-term follow-up.

This explains why an approval doesn’t immediately translate into hundreds of millions in quarterly revenue. The commercial curve of a cell therapy can be gradual and limited by the capacity of the healthcare system. The market must separate scientific validation from the pace of commercial ramp.

Why CRSP remains in research

CRISPR Therapeutics offers a benchmark. It demonstrates what obstacles await Beam and Intellia after a success: manufacturing, quality, centers, payer and durability. It also has in vivo, immuno-oncology and allogeneic therapies programs that can expand value beyond CASGEVY.

The company had approximately $2.36 billion in cash and investments as of June 30, 2026, the group’s largest position in dollar terms. Part of the increase from the previous quarter reflected a $600 million inflow of convertible senior notes. In Q2 the net loss was approximately 91.2 million and the R&D expenditure was approximately 67.2 million.^[15]

The paradox of the already validated company

An approved-stage company can carry less scientific risk than a Phase 1 biotech, but from a market perspective it does not offer the same percentage re-rating. The market already recognizes part of the validation. The next leap must come from commercial execution, label expansion or success of in vivo programs. CRSP is therefore a less pure candidate for the “next Moderna”, but one of the most important cases to understand what happens after validation.

Arcturus Therapeutics: The Most Literal Answer for Investors Seeking a New RNA Platform

If “next Moderna” is interpreted in the literal sense of successor to mRNA, Arcturus is one of the most relevant companies. The platform combines STARR self-amplifying RNA, LUNAR lipid delivery and manufacturing expertise. KOSTAIVE has provided regulatory validation to the self-amplifying mRNA technology in the vaccine field, while the real optionality for the market lies in the transition from vaccines to repeatable somatic therapies.

Why self-amplifying RNA is interesting

A self-amplifying RNA is designed to temporarily replicate its message within the cell, with the aim of obtaining greater protein expression using lower doses than conventional mRNA. In theory this can reduce material quantities and costs, but tolerability, duration of expression and immunogenicity must be demonstrated for each application.

Delivery remains the central issue. Delivering RNA to the correct tissue, achieving sufficient expression, and allowing repeated doses without toxicity or loss of efficacy is more difficult than producing a vaccine response. This is why ARCT-032 in cystic fibrosis and ARCT-810 in ornithine transcarbamylase deficiency are more important, for the platform thesis, than vaccine validation alone.

ARCT-032: the lung test

ARCT-032 aims to deliver CFTR mRNA to the airways of patients with fibrosis cystic. The company indicated completion of Phase 2 in the fourth quarter of 2026 and a decision on moving to Phase 3 in the same period. A reproducible functional signal in the lung would be important because extrahepatic delivery represents one of the most difficult frontiers of therapeutic RNA.^[16]

The benchmark is high. CFTR modulators have transformed the treatment of many patients. Arcturus must primarily address mutations that cannot be treated with modulators or offer a complementary profile. Clinical improvements will be needed, not just protein expression, and tolerability compatible with repeated inhalation doses.

ARCT-810: protein replacement via mRNA

ARCT-810 aims to make the liver produce the OTC enzyme via mRNA. The program is conceptually close to the original promise of mRNA medicine: providing temporary instructions for producing a therapeutic protein without permanently modifying the genome. The potential advantage is reversibility; the downside is the need for repeated doses.

Balance Sheet and Partnerships

Arcturus had approximately $191.5 million in cash, equivalents and investments as of June 30, 2026, and indicated runway through the end of 2028. The company benefits from partnerships, including its relationship with CSL, and a model that can generate milestones and royalties. In Q2 the net loss was in the order of 23.8 million and the R&D expenditure was around 17.5 million.

The partnership model reduces needs and commercial risk, but can also limit the economic share retained. The evaluation must consider not only the potential of the products, but geographic rights, cost sharing and royalties.

The hidden risk: being “Moderna-like” is not enough

The market has already seen many RNA companies fail in non-vaccine therapeutic translation. mRNA is a class, not a guarantee. Tissue, dose, formulation, target, frequency and therapeutic window determine the outcome. Arcturus must demonstrate that LUNAR and STARR offer real clinical advantage, not just technical elegance.

Sana Biotechnology: Immune-Evasive Cells and CAR-T Cells Created In Vivo

Sana Biotechnology proposes one of the most scientifically broad theses on the list. The Hypoimmune platform aims to create cells that can avoid immune recognition, potentially enabling allogeneic transplants without chronic immunosuppression. A second axis aims to generate CAR-T directly in the patient, avoiding part of the production complexity of autologous therapies.

UP421: proof-of-concept that rekindled the thesis

The UP421 proof-of-concept in type 1 diabetes showed transplanted islet cells capable of surviving, avoiding rejection and producing insulin without immunosuppression for over a year in the patient described. The result is conceptually powerful: if engineered cells could function for a long time without immunosuppressive drugs, the approach could change transplants, diabetes and cell therapy.^[17]

Caution is equally important. A single proof-of-concept does not establish reproducibility, duration, dose, safety or industrial process. UP421 is not the final commercial product. Sana must transfer the principle to SC451, a product derived from pluripotent stem cells, with production, characterization and quality control compatible with regulatory development.

SC451: from the clinical case to the industrial platform

SC451 aims to offer a one-time treatment for type 1 diabetes capable of achieving glycemic control without insulin exogenous and without immunosuppression. It’s a huge goal. The population is large, the necessary duration is very long and the safety threshold is high. The cells must survive, produce insulin in a regulated manner, avoid rejection and not generate unwanted proliferations.

The value of the platform depends on the switch between “can cells be invisible?” and “can we produce millions of standardized, safe, consistent and functional doses?”. It is the same distance that separates an academic discovery from a pharmaceutical company.

SG293: in vivo CAR-T as a second engine

SG293 aims to generate CAR-T cells directly in the body through targeted delivery. The approach, if effective, could eliminate collection, customized production, waiting times and part of the costs of autologous CAR-Ts. However, competition in the field of in vivo cell engineering is growing and the challenges are considerable: specificity of delivery, control of expression, expansion, persistence and risk of unwanted immunological effects.

Balance sheet and dilution

As of 30 June 2026 Sana had approximately 160.5 million dollars in cash, equivalents and investments and indicated runway until mid-2027. In Q2 it had incurred R&D expenses of approximately 30.7 million and a net loss in the order of 65 million. The company had also used ATM/equity tools, confirming that the need for capital is an integral part of the thesis.^[18]

The gap between proof-of-concept and mature clinical data makes further financing, partnerships or pipeline rationalization likely. Early success can improve harvesting conditions; a delay can reduce the negotiating leverage.

Prime Medicine: The Most Ambitious Platform, Still Awaiting Decisive Proof

Prime Medicine develops Prime Editing, an approach designed to make precise genetic changes without necessarily requiring double-strand breaks or external templates. In theory it can correct substitutions, small insertions and deletions and address a very large share of known pathogenic variants. The company has often described a theoretical ability to target approximately 90% of known disease-associated mutations; it is a statement about the potential of the technology, not a demonstration that 90% of diseases are clinically treatable.^[19]

PM577a in Wilson’s disease

PM577a is an in vivo program for Wilson’s disease. The IND was authorized in the United States and the company initiated a Phase 1/2 in 2026, with first data expected in 2027. The program aims to correct ATP7B mutations in the liver and represents a central test for delivery, precision and functionality of Prime Editing in vivo.

A favorable signal would be important even beyond Wilson, because it would demonstrate the possibility of performing more complex corrections directly in the patient. But the initial phase requires caution: the first patients are mainly used to evaluate safety, dose and proof-of-mechanism. Small numbers and short follow-up can produce great volatility without yet providing a definitive answer.

PM647 and AATD

PM647 brings Prime Medicine into alpha-1 antitrypsin deficiency, creating a conceptual comparison with BEAM-302. Beam already has human data and a pivotal pathway; Prime offers a different and potentially more versatile technology, but it needs to catch up on clinical distance. The CTA/IND was expected in Q3 2026.

PM359: Closest Path to BLA

PM359 is an ex vivo therapy developed for chronic granulomatous disease. The program has received RMAT designation and Prime Medicine indicated a possible BLA in 2027. This asset may provide a closer regulatory pathway as in vivo programs mature. As for Beam, the ex vivo/in vivo combination allows for the construction of two types of validation.

Finances and priorities

Prime Medicine had approximately 108.8 million dollars in cash, investments and restricted cash at 30 June 2026, with a runway indicated in 2027. In Q2 R&D spending was approximately 33.4 million and the net loss approximately 42.1 million. The company had also resolved an arbitration dispute with a payment of 5 million.^[19]

The relationship between platform ambition and resources imposes discipline. Prime cannot simultaneously develop every theoretical possibility. It will have to choose indications in which delivery, expected benefit and regulatory path allow a rapid and interpretable test. A partnership could finance breadth, but transfer some of the economy.

The risk of the platform being “too broad”

The promise of being able to correct many classes of mutations is fascinating, but the pharmaceutical value does not arise from the theoretical percentage of correctable variants. It arises from the ability to deliver the system to the tissue, achieve sufficient editing, avoid byproduct and off-target, produce benefit and industrialize the treatment. Each indication adds biological and regulatory complexity.

BioNTech: Moderna’s Major Peer, Not the “Next Moderna”

BioNTech is often cited as a natural answer because it shares the heritage of vaccines mRNA and has built a broad oncology pipeline. But the company is no small candidate waiting to become Moderna. It already has a large organization, global infrastructure, extraordinary capital and partnerships with groups such as Pfizer, Genentech/Roche and Bristol Myers Squibb. It is a strategic peer.

As of Q2 2026, BioNTech had approximately €16.6 billion in cash, equivalents and equity investments and had fourteen pivotal studies, including six mRNA oncology vaccine programs. The pipeline includes customized vaccines, off-the-shelf vaccines, bispecifics, ADCs and other immunomodulators.^[20]

Why the Moderna result is positive for BioNTech

A positive Phase 3 in oncology mRNA reduces skepticism over the entire class. It does not prove that every BioNTech vaccine works, because the target, neoantigenic algorithm, combination, setting and manufacturing differ. But it raises the plausibility that the immune system could be guided with RNA to reduce recurrence or progression in some cancers.

BNT113, developed in HPV16-positive head and neck cancer, and personalized programs with Roche are examples of how the company could benefit from a reevaluation of the class. BioNTech also has the capital to support large trials and tolerate failures without compromising the entire pipeline.

The risk of complexity

A very large pipeline can become difficult to evaluate. Success in one modality may be offset by high expense or delays in others. The market must distinguish which programs can support significant revenues, which are partner-funded and what economic share remains with BioNTech.

The large cash position reduces financial risk, but creates another question: how much return can the invested capital generate? Acquisitions, partnerships and internal development must produce assets that justify billions in R&D over time.

The Catalysts That Could Create the Next Validation Moment

A platform thesis can take years, but the market moves around precise windows. The timeline below brings together catalysts communicated or reasonably linked to available guidance. These are not guaranteed dates. Companies can change times, add analyses, delay filings or publish only part of the initially expected data.

SELLAS: dual axis REGAL and SLS009

REGAL remains the closest and binary catalyst. The final threshold is the eightieth pooled event, but the time between event and communication will depend on the closing and analysis process. The randomized frontline study of SLS009 adds a second readout in Q4 2026. The proximity of the two events may rapidly change how the market separates the value of GPS from the value of tambiciclib.

Beam: ERS, pivotal and possible BLA

BEAM-302 data and the progression of the pivotal cohort are central to establishing durability and consistency of the correction. In parallel, the possible BLA of risto-cel by the end of 2026 can move Beam towards a more mature regulatory phase. The company therefore has catalysts in two different modes.

Intellia: from statistics to commercialization

For NTLA the main catalyst is no longer the proof-of-concept: it is the acceptance and review of the lonvo-z BLA, followed by the eventual launch. Labels, follow-up requirements, payer discussions and speed of patient identification will be important.

CRSP: the catalyst becomes execution

CASGEVY is already approved. The market will observe number of patients activated and infused, center capacity, revenues and milestones. In vivo programs can add a second leg to the thesis, but commercial execution remains the immediate thermometer.

ARCT, SANA and PRME: the proof that transforms technology into medicine

For Arcturus the Phase 3 decision in cystic fibrosis is the key step. For Sana, the clinical entry of the industrialized product SC451 is more important than just the excitement around UP421. For Prime Medicine, early in vivo data and the possible BLA pathway of PM359 will determine whether Prime Editing’s theoretical breadth begins to translate into a regulatory platform.

The Cross-Cutting Risks a Ticker Ranking Tends to Hide

Each company presents specific risks, but there are problems common to almost all advanced platforms. They are often more important than a single endpoint, because they can limit multiple programs at once.

1. Early success does not make all assets equivalent

A platform shares tools, but each drug encounters different biology. The success of intismeran in melanoma does not guarantee success in every tumor. A positive Phase 3 of lonvo-z does not demonstrate that nex-z improves ATTR outcomes. The SERPINA1 correction does not demonstrate that each Beam target is editable with the same profile. The market tends to generalize too quickly after a validation and to deny the entire platform too quickly after a failure.

2. Surrogates and biomarkers may not become clinically beneficial

Reducing a pathological protein, increasing a functional one or obtaining measurable editing are necessary steps, but not always sufficient. The translation depends on the biological threshold, duration, reversibility of the disease and when the patient is treated. BEAM-302 will have to demonstrate that the correction modifies the course; PM577a and PM647 will have to go beyond proof-of-editing; RNA therapies must produce a clinically useful amount of protein.

3. Permanence: therapeutic advantage and safety responsibility

Gene editing and cell engineering can offer a one-time treatment, but a permanent error cannot simply be suspended like a tablet. Off-target, unwanted insertions/deletions, cellular transformation, immunogenicity and late consequences require long-term monitoring. A reassuring initial safety database does not eliminate the need for years of follow-up.

4. Delivery: the real technology moat

Many platforms can design a payload. Few can deliver it to the correct tissue with efficiency, specificity and tolerability. The liver is relatively accessible to lipid nanoparticles; lung, muscle, brain and spinal cord have different barriers. The company that solves extrahepatic delivery can obtain a more important advantage than the individual editor.

5. CMC and manufacturing

A personalized therapy requires sequencing, design and manufacturing on a per-patient basis. An ex vivo cell therapy requires complex logistical chains and controls. An allogeneic product must be consistent between batches and maintain function. An in vivo editor must have purity, stability and control of impurities. Regulators can accept the biology and still ask for more work on the production process.

6. The theoretical market does not coincide with the treatable market

The TAM often uses prevalence or incidence, but the real market depends on diagnosis, eligibility, centers, insurance, alternatives, perceived risk and willingness to treat. CASGEVY proves it: a large population does not immediately convert to infusions. Lonvo-z will have to compete with effective prophylactics. SC451, if it worked, would have to face a huge population but a very high safety threshold.

7. Price and reimbursement of one-time therapies

A potentially curative therapy can justify a high price compared to years of chronic treatment. But the value depends on durability. Payers and health systems may require outcome-based agreements, installment payments or real-world evidence. The company must finance production and launch before fully collecting the value.

8. Capital management

A positive outcome may cause management to expand the pipeline too quickly, build a sales force prematurely, or raise capital without discipline. A negative result can lead to late renovations. In platform companies, capital allocation is a form of scientific selection: choosing which programs not to finance is as important as choosing which ones to develop.

Bull, Base and Bear Scenarios for the “Next Moderna” Theme

Bull scenario: more platforms reach validation clinic

In a favorable scenario, Moderna’s success is not an isolated event but the beginning of a new phase. REGAL shows compelling OS benefit; lonvo-z passes the review and is adopted; BEAM-302 confirms pivotal data; risto-cel reaches the BLA; Arcturus demonstrates therapeutic delivery; Sana transfers Hypoimmune from UP421 to SC451; Prime Medicine produces in vivo functional editing. Capital returns to biotech and partnerships increase.

In this scenario there is not a single next Moderna. The market creates multiple winners, but quickly differentiates companies with delivery, manufacturing and capital from those with isolated programs. BEAM and NTLA benefit from class validation; SLS can experience the biggest corporate leap if GPS reaches the endpoint; ARCT receives the most direct reward from the expansion of RNA beyond vaccines.

Baseline scenario: few successes, strong selection

It is probably the most realistic scenario. Some programs work, others fail. FDA requires follow-up and CMC; launches are slower than estimated; companies raise capital after data. Evaluations reward controlled results and penalize proof-of-concepts that are too small.

In this context, the quality of the trial matters more than the narrative. A positive but modest REGAL can produce a lower-than-expected re-rating. Lonvo-z may be approved but take time to adopt. BEAM-302 can maintain strong correction without yet demonstrating definitive clinical endpoint. Sana and Prime can produce attractive signals that do not eliminate the need for capital.

Bear scenario: Moderna validation remains difficult to replicate

In the adverse case, subsequent results show that Moderna’s success is highly specific to the product, setting and combination with Keytruda. REGAL fails; the lonvo-z review gets complicated; basic/prime editing programs meet safety or delivery; therapeutic RNA does not achieve efficacy; capital markets close.

Companies with strong balance sheets survive and refocus. Those with short runways collect at depressed prices or seek partnerships. CRSP and BioNTech have greater capacity to absorb failures. BEAM has capital and multiple programs. SLS, Sana and Prime present greater sensitivity to the single catalyst or the need for new equity.

Final Ranking: Who Could Really Be the Next Moderna?

A single ranking hides too much. The most useful conclusion is to assign a winner to each definition.

The overall editorial hierarchy

The most honest conclusion is threefold: BEAM is the best “next Moderna” as a structure; NTLA is the closest to commercial validation of in vivo editing; SLS is the closest candidate for the next major binary re-rating from Phase 3.

This distinction is more useful than a single ticker because it forces you to specify the source of the potential. An investor looking for a diversified platform is asking a different question than someone looking for the closest pivotal catalyst. Confusing the two leads to underestimating the risk of SLS or underestimating the time needed for Sana and Prime Medicine.

The market will remember August 19, 2026 as the day a Phase 3 changed the way we look at Moderna. The next similar event will not necessarily be a +176% in one session, and it will not necessarily be produced by mRNA. It will be the moment when a technology or asset goes from promise to proof, forcing the market to rebuild the valuation from scratch.

Primary Sources and References

Sources were reviewed through August 20, 2026. SEC filings and official press releases prevail over market summaries. Price data come from market feeds and may differ slightly by provider, session and adjustments.

1. Reuters — Merck and Moderna: INTerpath-001 reaches RFS and DMFS in melanoma, August 19, 2026.
2. Merck — data to five years of intismeran autogene plus Keytruda, June 1, 2026.
3. Moderna — Q2 2026 financial results and business update.
4. SELLAS — Exhibit 99.1, Q2 results 2026 and corporate update.
5. SELLAS — Form 10-Q for the quarter ended March 31, 2026.
6. SELLAS Investor Relations — archive of REGAL and IDMC press releases.
7. ClinicalTrials.gov — REGAL Phase 3, NCT04229979.
8. SELLAS Form 10-Q — data and clinical description of SLS009/tambiciclib.
9. SELLAS Investor Relations — launching randomized frontline study of SLS009.
10. SELLAS Form 10-Q — licenses, capital structure, warrants and ATM.
11. Beam Therapeutics — Q2 results 2026. 2026.
12. Beam Therapeutics — clinical update BEAM-302, March 25 2026.
13. Intellia Therapeutics — Q2 2026 results and business update.
14. The New England Journal of Medicine — Phase 3 HAELO by lonvoguran ziclumeran.
15. CRISPR Therapeutics — Q2 2026 results and CASGEVY update.
16. Arcturus Therapeutics — Q2 2026 results and pipeline update.
17. Sana Biotechnology — follow-up and publication of the UP421 proof-of-concept.
18. Sana Biotechnology — Q2 2026 results.
19. Prime Medicine — filing Q2 2026, PM577a, PM647 and PM359 programs.
20. BioNTech — Q2 2026 results and pivotal pipeline.
21. FDA — approval of CASGEVY in sickle cell disease.
22. Moderna — official pipeline.
23. SEC EDGAR — corporate filings and verification of the structure of the capital.
24. Stocktwits — retail sentiment, survey dated 20 August 2026.
25. Alpaca Market Data — prices and historical bars used in charts.